Related Experiment Video

Updated: Sep 3, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 3, 2013

[Prostate cancer screening]

Arnauld Villers, Xavier Rébillard, Michel Soulié

    Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
    |May 27, 2003
    PubMed

    Abstract:

    Prostate cancer has become the most frequent cancer and the second cause of cancer mortality in men. This public health problem is becoming increasingly important due to the increasing life expectancy. At the present time, prostate cancer will be discovered in one in every eight men during their lifetime. Prostate cancer represents 25% of all new cases of male cancers. Prostate cancer screening is designed to detect early stage, asymptomatic prostate cancer, as the patient's chances of cure are higher when the cancer is diagnosed at an early stage. The conclusions of the ANAES evaluation in 1998 did not recommend mass screening for prostate cancer. Several international prospective randomized studies based on serum PSA assay, sometimes associated with digital rectal examination, are currently underway. France is participating in the European ERSPC study (European Randomized Study of Screening for Cancer Prostate) and is organizing a national study on high-risk populations. While waiting for the final results of these studies, a recommendation needs to be proposed to inform general practitioners and specialists about optimal use of the currently available tests. Based on the conclusions of its oncology committee (composed of urologists, medical oncologists, radiotherapists, pathologists and radiologists), the Association Française d'Urologie proposes a recommendation concerning prostate cancer screening and defines its modalities, especially concerning the target population, screening tests and the information given to men before screening. The Association Française d'Urologie recommends prostate cancer screening by PSA assay (prostate specific antigen) and digital rectal examination annually between the ages of 50 and 75 years, and from the age of 45 years in men with a family or ethnic risk. If total PSA is above the normal value of the test or if digital rectal examination is abnormal, referral to a urologist is recommended. Information concerning the limits, benefits and risks of screening and the available treatment options must be given before performing these examinations.

    More Related Videos

    Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
    05:35

    Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

    Published on: June 6, 2025

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Related Experiment Videos

    Last Updated: Sep 3, 2026

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
    13:19

    Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

    Published on: November 3, 2013

    Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance
    05:35

    Transperineal Prostate Biopsy Using a Cone-shaped Double-hole Method with Dual-plane Probe Guidance

    Published on: June 6, 2025

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    Related Concept Videos

    Disorders of the Male Reproductive System01:20

    Disorders of the Male Reproductive System

    Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
    Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

    Articles linked to this work by shared authors, journal, and citation graph.

    Longitudinal Economic Burden for Non-Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database.

    European urology open science·2026

    Long-term Prediction of Metastatic Recurrence in Patients Candidate to Radical Prostatectomy Using MRI and Targeted Biopsy: Insights into Tumor Zonal Origin.

    European urology oncology·2026

    Prostate Cancer Mortality in Men not Attending a Population-based Screening Program: The 'Good', the 'Bad', and the 'Ugly' After 20-yr Follow-up in the European Randomised study of Screening for Prostate Cancer.

    European urology open science·2026

    ISUP 2 prostate cancer with suspicion of extraprostatic extension on MRI: Prostatectomy results and oncologic outcomes.

    Urologic oncology·2026

    PI-RADS v2 and Adverse Prostate Cancer Outcomes: A Cross-cohort Replication Study Across Three Centers.

    European urology oncology·2026

    Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study).

    European urology oncology·2026

    ["Connected device for monitoring patients treated by prostatectomy: Implementation and qualitative assessment"].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024

    [Role of nurses specializing in oncology to support the care journey for patients with penile cancer].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024

    [Pre- and post-prostatectomy rehabilitation by the certified nurse-urologist pair (REHAB): Feasibility study].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024

    [Genitourinary complications after pelvic radiotherapy: Diagnosis and management].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024

    [Male contraception].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023

    [The urologist's role in assisted reproductive technology (ART)].

    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023

    The Mediating Role of Patient Activation in the Association Between Illness Perception and Self-Management Behavior Among Patients with Oral Cancer.

    Patient preference and adherence·2026

    Carcinoid Heart Disease Presenting as Cardiogenic Shock: A Case Report.

    Cureus·2026

    Erratum: Preclinical study of using multiphoton microscopy to diagnose liver cancer and differentiate benign and malignant liver lesions (Erratum).

    Journal of biomedical optics·2026

    A cfDNA-based DNA methylation classifier for distinguishing prostate cancer from benign prostatic hyperplasia.

    Prostate international·2026

    Nanosystem-Mediated Intercellular Crosstalk Modulation in the Tumor Microenvironment for Enhanced Cancer Immunotherapy.

    Drug design, development and therapy·2026

    Complementary detection of clinically significant prostate cancer by magnetic resonance imaging fusion-targeted and systematic transrectal ultrasound-guided biopsy: influence of prostate-specific antigen and prostate-specific antigen density in a retrospective paired cohort.

    Prostate international·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us